Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

Interleukin (IL-) 6 is a key factor in the inflammatory processes of rheumatoid arthritis. Several biologic agents target the IL-6 signaling pathway, including sarilumab, a monoclonal antibody that blocks the IL-6 receptor and inhibits IL-6-mediated cis- and trans-signaling. A careful analysis of th...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Annett Klinder, Janine Waletzko-Hellwig, Marie-Luise Sellin, Anika Seyfarth-Sehlke, Markus Wolfien, Franziska Prehn, Rainer Bader, Anika Jonitz-Heincke
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: MDPI AG 2022-06-01
Sarja:Pharmaceutics
Aiheet:
Interleukin 6
sarilumab
soluble IL-6 receptor
antagonism
human osteoblasts
osteogenic differentiation
Linkit:https://www.mdpi.com/1999-4923/14/7/1390

Internet

https://www.mdpi.com/1999-4923/14/7/1390

Samankaltaisia teoksia